Ventrus Biosciences Inc Share Price Nasdaq
Equities
US9228221019
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 24.2M 1.92B | Sales 2025 * | 14.52M 1.15B | Capitalization | 76.21M 6.04B |
---|---|---|---|---|---|
Net income 2024 * | -52M -4.12B | Net income 2025 * | -54M -4.28B | EV / Sales 2024 * | 3.15 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.25 x |
P/E ratio 2024 * |
-1.47
x | P/E ratio 2025 * |
-1.45
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.94% |
Latest transcript on Ventrus Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Jason Okazaki
CEO | Chief Executive Officer | 48 | 29/03/20 |
Anuj Gaggar
CTO | Chief Tech/Sci/R&D Officer | 46 | 11-07 |
William Delaney
CTO | Chief Tech/Sci/R&D Officer | 52 | 31/05/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Mahony
BRD | Director/Board Member | 59 | 13/12/17 |
Gina Consylman
BRD | Director/Board Member | 52 | 19/10/20 |
William Ringo
CHM | Chairman | 78 | 30/06/14 |
1st Jan change | Capi. | |
---|---|---|
+14.33% | 74.45B | |
+11.35% | 9.18B | |
+60.16% | 5.03B | |
-12.85% | 5.02B | |
+1.60% | 3.82B | |
-19.20% | 2.41B | |
+19.25% | 2.39B | |
-27.46% | 2.27B | |
+24.62% | 2.26B |